

Lamivir[®]

Lamivudine 100 mg tablet

Presentation

Each film coated Lamivir[®] tablet contains Lamivudine INN 100 mg.

Description

Lamivudine is a synthetic nucleoside analogue with activity against Hepatitis B Virus (HBV) and Human Immunodeficiency Virus (HIV).

Indications

Lamivir is indicated for the treatment of chronic hepatitis B associated with evidence of hepatitis B viral replication and active liver inflammation.

Dosage and Administration

The recommended oral dose of Lamivudine for the treatment of chronic hepatitis B in adults is 100 mg once daily. Treatment should be continued if there is no loss of efficacy and until adequate seroconversion is achieved.

Side Effects

Nausea, vomiting, diarrhoea, abdominal pain, cough, headache, insomnia, malaise, fever, rash, alopecia, muscle disorders, nasal symptoms, peripheral neuropathy may occur. Sometimes neutropenia and anemia; thrombocytopenia; lactic acidosis, raised liver enzymes and serum amylase have been reported.

Contraindications

Lamivudine is contraindicated in patients with hypersensitivity to any of the components of the product.

Precautions

Patients should be assessed before giving treatment with Lamivudine. Safety and efficacy of Lamivudine have not been established in patients with decompensated liver disease, pediatric patients, patients dually infected with Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV), hepatitis delta. Reduction in dosage is recommended for patients with impaired renal function.

Use in Pregnancy and Lactation

There are no adequate and well controlled studies in pregnant woman. Lamivudine should be used in pregnancy if the potential benefits outweigh the risks. Mother should be instructed not to breastfeed if they are receiving Lamivudine.

Commercial pack

Lamivir[®] : Each box contains 2 blister strips of 10 tablets.

Manufactured by



Incepta Pharmaceuticals Ltd.

Dhaka, Bangladesh

® Registered Trademark

PTG : 058/12-00/20000 IMP
I 041200 LAT